Risk of natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: a retrospective analysis of data from four clinical studies by Ho, Pei-Ran, Koendgen, Harold, Campbell, Nolan, Haddock, Bill, Richman, Sandra, Chang, Ih

Get full text

Modeling the Efficacy of Natalizumab in Multiple Sclerosis Patients Who Switch From Every‐4‐Week Dosing to Extended‐Interval Dosing by Chang, Ih, Muralidharan, Kumar Kandadi, Campbell, Nolan, Ho, Pei‐Ran

Get full text

Discontinuation of denosumab and associated fracture incidence: Analysis from the Fracture Reduction Evaluation of Denosumab in Osteoporosis Every 6 Months (FREEDOM) Trial by Brown, Jacques P, Roux, Christian, Törring, Ove, Ho, Pei‐Ran, Beck Jensen, Jens‐Erik, Gilchrist, Nigel, Recknor, Christopher, Austin, Matt, Wang, Andrea, Grauer, Andreas, Wagman, Rachel B

Get full text

The risk of PML from natalizumab – Authors' reply by Ho, Pei-Ran, Campbell, Nolan, Chang, Ih

Get full text

Real-world disability improvement in patients with relapsing–remitting multiple sclerosis treated with natalizumab in the Tysabri Observational Program by Wiendl, Heinz, Spelman, Tim, Butzkueven, Helmut, Kappos, Ludwig, Trojano, Maria, Su, Ray, Campbell, Nolan, Ho, Pei-Ran, Licata, Stephanie

Get full text

Clinical outcomes in patients who discontinue natalizumab therapy after 2 years in the Tysabri® Observational Program (TOP) by Butzkueven, Helmut, Trojano, Maria, Kappos, Ludwig, Spelman, Tim, Wiendl, Heinz, Rosales, Karen, Su, Ray, Licata, Stephanie, Ho, Pei-Ran, Campbell, Nolan

Get full text

No evidence for loss of natalizumab effectiveness with every-6-week dosing: a propensity score–matched comparison with every-4-week dosing in patients enrolled in the Tysabri Obser... by Butzkueven, Helmut, Kappos, Ludwig, Spelman, Tim, Trojano, Maria, Wiendl, Heinz, Su, Ray, Liao, Shirley, Hyde, Robert, Licata, Stephanie, Ho, Pei-Ran, Campbell, Nolan

Get full text

Natalizumab versus fingolimod for patients with active relapsing-remitting multiple sclerosis: results from REVEAL, a prospective, randomised head-to-head study by Butzkueven, Helmut, Licata, Stephanie, Jeffery, Douglas, Arnold, Douglas L, Filippi, Massimo, Geurts, Jeroen JG, Santra, Sourav, Campbell, Nolan, Ho, Pei-Ran

Get full text

Declining Rates of Osteoporosis Management Following Fragility Fractures in the U.S., 2000 Through 2009 by Balasubramanian, Akhila, Tosi, Laura L, Lane, Joseph M, Dirschl, Douglas R, Ho, Pei-Ran, O’Malley, Cynthia D

Get full text

Statistical analysis of PML incidences of natalizumab-treated patients from 2009 to 2016: outcomes after introduction of the Stratify JCV® DxSelect™ antibody assay by Campagnolo, Denise, Dong, Qunming, Lee, Lily, Ho, Pei-Ran, Amarante, Diogo, Koendgen, Harold

Get full text

A 24-Month Study Evaluating the Efficacy and Safety of Denosumab for the Treatment of Men With Low Bone Mineral Density: Results From the ADAMO Trial by Langdahl, Bente L, Teglbjærg, Christence Stubbe, Ho, Pei-Ran, Chapurlat, Roland, Czerwinski, Edward, Kendler, David L, Reginster, Jean-Yves, Kivitz, Alan, Lewiecki, E. Michael, Miller, Paul D, Bolognese, Michael A, McClung, Michael R, Bone, Henry G, Ljunggren, Östen, Abrahamsen, Bo, Gruntmanis, Ugis, Yang, Yu-Ching, Wagman, Rachel B, Mirza, Faisal, Siddhanti, Suresh, Orwoll, Eric

Get full text

Denosumab Treatment in Postmenopausal Women with Osteoporosis Does Not Interfere with Fracture-Healing: Results from the FREEDOM Trial by Adami, Silvano, Libanati, Cesar, Boonen, Steven, Cummings, Steven R, Ho, Pei-Ran, Wang, Andrea, Siris, Ethel, Lane, Joseph

Get full text

The 5-year Tysabri global observational program in safety (TYGRIS) study confirms the long-term safety profile of natalizumab treatment in multiple sclerosis by Foley, John, Carrillo-Infante, Cynthia, Smith, Jonathan, Evans, Karleyton, Ho, Pei-Ran, Lee, Lily, Kasliwal, Rachna, Stangel, Martin, Vermersch, Patrick, Hutchinson, Michael, Marinelli, Fabiana, Smirnakis, Karen

Get full text

Treatment Satisfaction in Postmenopausal Women Suboptimally Adherent to Bisphosphonates Who Transitioned to Denosumab Compared With Risedronate or Ibandronate by Palacios, Santiago, Agodoa, Irene, Bonnick, Sydney, Van den Bergh, Joop P, Ferreira, Irene, Ho, Pei-Ran, Brown, Jacques P

Get full text

Benefits of early treatment with natalizumab: a real-world study by Ontaneda, Daniel, Mowry, Ellen M., Newsome, Scott D, Naismith, Robert T., Nicholas, Jacqueline, Fisher, Elizabeth, de Moor, Carl, Bohn, Justin, Ho, Pei-Ran, Sandrock, Al, Rudick, Richard, Williams, James R.

Get full text

Considerations for characterizing the risk of PML in natalizumab-treated patients by Koendgen, Harold, Ho, Pei-Ran, Chang, Ih

Get full text

Exposure–disease response analysis of natalizumab in subjects with multiple sclerosis by Muralidharan, Kumar Kandadi, Steiner, Deb, Amarante, Diogo, Ho, Pei-Ran, Mikol, Dan, Elkins, Jacob, Subramanyam, Meena, Nestorov, Ivan

Get full text

Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label... by Kapoor, Raju, Chang, Ih, Deykin, Aaron, Forrestal, Fiona, Lucas, Nisha, Yu, Bei, Arnold, Douglas L, Freedman, Mark S, Hartung, Hans-Peter, Jeffery, Douglas, Sellebjerg, Finn, Cadavid, Diego, Mikol, Dan, Bartholomé, Emmanuel, D'Hooghe, Marie, Devonshire, Virginia, Grand'Maison, François, Jacques, François, Lapierre, Yves, Morrow, Sarah, Stetkarova, Ivana, Talabova, Marika, Frederiksen, Jette, Kant, Matthias, Petersen, Thor, Eralinna, Juha-Pekka, Brassat, David, Brochet, Bruno, Vermersch, Patrick, Vukusi, Sandra, Baum, Karl, Maeurer, Mathias, Meuth, Sven, Hardiman, Orla, Achiron, Anat, Karussis, Dimitrios, Bergamaschi, Roberto, Grimaldi, Luigi, Salvetti, Marco, Scarpini, Elio, Sola, Patrizia, Zaffaroni, Mauro, Frequin, Stephan, Hupperts, Raymond, Killestein, Joep, Schrijver, Hans, van Munster, Erik, Drozdowski, Wieslaw, Fryze, Waldemar, Klodowska-Duda, Gabriela, Motta, Ewa, Podemski, Ryszard, Selmaj, Krzysztof, Stepien, Adam, Tutaj, Andrzej, Boyko, Alexey, Escartin, Antonio, Garcia-Merino, Antonio, Hernandez Perez, Miguel Angel, Ayuso, Guillermo Izquierdo, Lallana, José Meca, Gairin, Xavier Montalban, Gunnarsson, Martin, Roshanisefat, Homayoun, Sundstrom, Peter, Gran, Bruno, Kapoor, Raju, Mattison, Paul, Pearson, Owen, Rashid, Waqar, Rog, David, Silber, Eli, Bandari, Daniel, Camac, Ann, Cohan, Stanley, Fabian, Michelle, Florin, Jack, Freedman, Steven, Garwacki, Dennis, Goldman, Myla, Harrison, Daniel, Herrman, Craig, Huang, Deren, Jeffery, Douglas, Kamin, Stephen, Langer-Gould, Annette, Mattson, David, Miller, Tamara, Moses, Harold, Muley, Suraj, Nielsen, Allen, Pardo, Gabriel, Picone, MaryAnn, Robertson, Derrick, Sheppard, Christopher, Thrower, Ben, Twyman, Cary, Waubant, Emmanuelle, Yadav, Vijayshree, Zabad, Rana

Get full text

Functional recovery following nerve injury and repair by silicon tubulization: comparison of laminin-fibronectin, dialyzed plasma, collagen gel, and phosphate buffered solution by Terris, David J, Cheng, Elbert T, Utley, David S, Tarn, Derjung M, Ho, Pei-Ran, Verity, A.Neil

Get full text

Results of termino-lateral neurorrhaphy to original and adjacent nerves by Zhang, Feng, Cheng, Chester, Chin, Brian T., Ho, Pei-Ran, Weibel, Timothy J., Lineaweaver, William C., Buncke, Harry J.

Get full text